Real-World Experience of Dupilumab Treatment for Patients with COPD – A Single Center Prospective Study
In this case-series, dupilumab was shown to be well tolerated and was associated with lower rates of exacerbations and improved symptoms. These outcomes were supported by patient reported outcome measurements.
Authors
- Amir Bar‐Shai (ORCID: https://orcid.org/0000-0001-9364-6887)
- Aviv Kupershmidt (ORCID: https://orcid.org/0000-0003-4224-4807)
- Inbal Friedman Regev
- Ophir Freund (ORCID: https://orcid.org/0000-0002-7272-5284)
- Liran Levy (ORCID: https://orcid.org/0000-0001-6368-8015)
- Doron Cohn‐Schwartz
- Omer Meoded
- Tala Arnaout
- Sharon Enghelberg
Institutions
- Tel Aviv Sourasky Medical Center (IL)
- Sheba Medical Center (IL)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/copd.s525781
- Citations
- 4
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.66